Involvement of FLIP in 2-methoxyestradiol-induced tumor regression in transgenic adenocarcinoma of mouse prostate model

Manonmani Ganapathy, Rita Ghosh, Xie Jianping, Xiaoping Zhang, Roble Bedolla, John Schoolfield, I. Tien Yeh, Dean A. Troyer, Aria F. Olumi, Addanki P Kumar

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Purpose: The purpose of this study is to investigate whether Fas-associated death domain interleukin-1 converting enzyme like inhibitory protein (FLIP) inhibition is a therapeutic target associated with 2-methoxyestradiol (2-ME 2) - mediated tumor regression. Experimental Design: Expression and levels of FLIP were analyzed using (a) real-time PCR and immunoblot analysis in androgen-independent PC-3 cells treated with the newly formulated 2-ME 2 and (b) immunohistochemistry in different Gleason pattern human prostate tumors. Transient transfections and chromatin immunoprecipitation (ChIP) assays were used to identify the transcription factors that regulate FLIP. Involvement of FLIP in 2-ME 2-induced tumor regression was evaluated in transgenic adenocarcinoma mouse prostate (TRAMP) mice. Results: High Gleason pattern (5+5) human prostate tumors exhibit significant increase in FLIP compared with low Gleason pattern 3+3 (P = <0.04). 2-ME 2 reduced the levels and promoter activity of FLIP (P = 0.001) in PC-3 cells. Transient expression assays show sequences between -503/+242 being sufficient for 2-ME 2- induced inhibition of FLIP promoter activity. Cotransfection experiments show that overexpression of Sp1 activated, whereas Sp3 inhibited, Sp1 transactivation of FLIP promoter activity (P = 0.0001). 2-ME 2 treatment reduced binding of Sp1 to the FLIP promoter as evidenced by ChIP. Further, levels of FLIP associated with Fas or FADD decreased, whereas cleavage of caspase-8, levels of Bid, and apoptosis increased in response to 2-ME 2 treatment in PC-3 cells. Administration of 2-ME 2 regressed established prostate tumors in TRAMP mice that were associated with reduced expression of FLIP and Sp1. Conclusion: Targeting Sp1-mediated FLIP signaling pathway may provide a novel approach for prostate cancer management.

Original languageEnglish (US)
Pages (from-to)1601-1611
Number of pages11
JournalClinical Cancer Research
Volume15
Issue number5
DOIs
StatePublished - Mar 1 2009

Fingerprint

Mercaptoethanol
Transgenic Mice
Prostate
Adenocarcinoma
Neoplasms
Chromatin Immunoprecipitation
Caspase 1
2-methoxyestradiol
Caspase 8
Transcriptional Activation
Androgens
Transfection
Real-Time Polymerase Chain Reaction
Prostatic Neoplasms
Research Design
Transcription Factors
Therapeutics
Immunohistochemistry
Apoptosis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Involvement of FLIP in 2-methoxyestradiol-induced tumor regression in transgenic adenocarcinoma of mouse prostate model. / Ganapathy, Manonmani; Ghosh, Rita; Jianping, Xie; Zhang, Xiaoping; Bedolla, Roble; Schoolfield, John; Yeh, I. Tien; Troyer, Dean A.; Olumi, Aria F.; Kumar, Addanki P.

In: Clinical Cancer Research, Vol. 15, No. 5, 01.03.2009, p. 1601-1611.

Research output: Contribution to journalArticle

Ganapathy, Manonmani ; Ghosh, Rita ; Jianping, Xie ; Zhang, Xiaoping ; Bedolla, Roble ; Schoolfield, John ; Yeh, I. Tien ; Troyer, Dean A. ; Olumi, Aria F. ; Kumar, Addanki P. / Involvement of FLIP in 2-methoxyestradiol-induced tumor regression in transgenic adenocarcinoma of mouse prostate model. In: Clinical Cancer Research. 2009 ; Vol. 15, No. 5. pp. 1601-1611.
@article{ff8bd3a03dff405bb85bb0bcc86f74b3,
title = "Involvement of FLIP in 2-methoxyestradiol-induced tumor regression in transgenic adenocarcinoma of mouse prostate model",
abstract = "Purpose: The purpose of this study is to investigate whether Fas-associated death domain interleukin-1 converting enzyme like inhibitory protein (FLIP) inhibition is a therapeutic target associated with 2-methoxyestradiol (2-ME 2) - mediated tumor regression. Experimental Design: Expression and levels of FLIP were analyzed using (a) real-time PCR and immunoblot analysis in androgen-independent PC-3 cells treated with the newly formulated 2-ME 2 and (b) immunohistochemistry in different Gleason pattern human prostate tumors. Transient transfections and chromatin immunoprecipitation (ChIP) assays were used to identify the transcription factors that regulate FLIP. Involvement of FLIP in 2-ME 2-induced tumor regression was evaluated in transgenic adenocarcinoma mouse prostate (TRAMP) mice. Results: High Gleason pattern (5+5) human prostate tumors exhibit significant increase in FLIP compared with low Gleason pattern 3+3 (P = <0.04). 2-ME 2 reduced the levels and promoter activity of FLIP (P = 0.001) in PC-3 cells. Transient expression assays show sequences between -503/+242 being sufficient for 2-ME 2- induced inhibition of FLIP promoter activity. Cotransfection experiments show that overexpression of Sp1 activated, whereas Sp3 inhibited, Sp1 transactivation of FLIP promoter activity (P = 0.0001). 2-ME 2 treatment reduced binding of Sp1 to the FLIP promoter as evidenced by ChIP. Further, levels of FLIP associated with Fas or FADD decreased, whereas cleavage of caspase-8, levels of Bid, and apoptosis increased in response to 2-ME 2 treatment in PC-3 cells. Administration of 2-ME 2 regressed established prostate tumors in TRAMP mice that were associated with reduced expression of FLIP and Sp1. Conclusion: Targeting Sp1-mediated FLIP signaling pathway may provide a novel approach for prostate cancer management.",
author = "Manonmani Ganapathy and Rita Ghosh and Xie Jianping and Xiaoping Zhang and Roble Bedolla and John Schoolfield and Yeh, {I. Tien} and Troyer, {Dean A.} and Olumi, {Aria F.} and Kumar, {Addanki P}",
year = "2009",
month = "3",
day = "1",
doi = "10.1158/1078-0432.CCR-08-1389",
language = "English (US)",
volume = "15",
pages = "1601--1611",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Involvement of FLIP in 2-methoxyestradiol-induced tumor regression in transgenic adenocarcinoma of mouse prostate model

AU - Ganapathy, Manonmani

AU - Ghosh, Rita

AU - Jianping, Xie

AU - Zhang, Xiaoping

AU - Bedolla, Roble

AU - Schoolfield, John

AU - Yeh, I. Tien

AU - Troyer, Dean A.

AU - Olumi, Aria F.

AU - Kumar, Addanki P

PY - 2009/3/1

Y1 - 2009/3/1

N2 - Purpose: The purpose of this study is to investigate whether Fas-associated death domain interleukin-1 converting enzyme like inhibitory protein (FLIP) inhibition is a therapeutic target associated with 2-methoxyestradiol (2-ME 2) - mediated tumor regression. Experimental Design: Expression and levels of FLIP were analyzed using (a) real-time PCR and immunoblot analysis in androgen-independent PC-3 cells treated with the newly formulated 2-ME 2 and (b) immunohistochemistry in different Gleason pattern human prostate tumors. Transient transfections and chromatin immunoprecipitation (ChIP) assays were used to identify the transcription factors that regulate FLIP. Involvement of FLIP in 2-ME 2-induced tumor regression was evaluated in transgenic adenocarcinoma mouse prostate (TRAMP) mice. Results: High Gleason pattern (5+5) human prostate tumors exhibit significant increase in FLIP compared with low Gleason pattern 3+3 (P = <0.04). 2-ME 2 reduced the levels and promoter activity of FLIP (P = 0.001) in PC-3 cells. Transient expression assays show sequences between -503/+242 being sufficient for 2-ME 2- induced inhibition of FLIP promoter activity. Cotransfection experiments show that overexpression of Sp1 activated, whereas Sp3 inhibited, Sp1 transactivation of FLIP promoter activity (P = 0.0001). 2-ME 2 treatment reduced binding of Sp1 to the FLIP promoter as evidenced by ChIP. Further, levels of FLIP associated with Fas or FADD decreased, whereas cleavage of caspase-8, levels of Bid, and apoptosis increased in response to 2-ME 2 treatment in PC-3 cells. Administration of 2-ME 2 regressed established prostate tumors in TRAMP mice that were associated with reduced expression of FLIP and Sp1. Conclusion: Targeting Sp1-mediated FLIP signaling pathway may provide a novel approach for prostate cancer management.

AB - Purpose: The purpose of this study is to investigate whether Fas-associated death domain interleukin-1 converting enzyme like inhibitory protein (FLIP) inhibition is a therapeutic target associated with 2-methoxyestradiol (2-ME 2) - mediated tumor regression. Experimental Design: Expression and levels of FLIP were analyzed using (a) real-time PCR and immunoblot analysis in androgen-independent PC-3 cells treated with the newly formulated 2-ME 2 and (b) immunohistochemistry in different Gleason pattern human prostate tumors. Transient transfections and chromatin immunoprecipitation (ChIP) assays were used to identify the transcription factors that regulate FLIP. Involvement of FLIP in 2-ME 2-induced tumor regression was evaluated in transgenic adenocarcinoma mouse prostate (TRAMP) mice. Results: High Gleason pattern (5+5) human prostate tumors exhibit significant increase in FLIP compared with low Gleason pattern 3+3 (P = <0.04). 2-ME 2 reduced the levels and promoter activity of FLIP (P = 0.001) in PC-3 cells. Transient expression assays show sequences between -503/+242 being sufficient for 2-ME 2- induced inhibition of FLIP promoter activity. Cotransfection experiments show that overexpression of Sp1 activated, whereas Sp3 inhibited, Sp1 transactivation of FLIP promoter activity (P = 0.0001). 2-ME 2 treatment reduced binding of Sp1 to the FLIP promoter as evidenced by ChIP. Further, levels of FLIP associated with Fas or FADD decreased, whereas cleavage of caspase-8, levels of Bid, and apoptosis increased in response to 2-ME 2 treatment in PC-3 cells. Administration of 2-ME 2 regressed established prostate tumors in TRAMP mice that were associated with reduced expression of FLIP and Sp1. Conclusion: Targeting Sp1-mediated FLIP signaling pathway may provide a novel approach for prostate cancer management.

UR - http://www.scopus.com/inward/record.url?scp=63449135315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63449135315&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-08-1389

DO - 10.1158/1078-0432.CCR-08-1389

M3 - Article

C2 - 19223508

AN - SCOPUS:63449135315

VL - 15

SP - 1601

EP - 1611

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 5

ER -